Alkermes (ALKS) PT Lowered to $45 at BofA/Merrill Lynch; Sees Loss in 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Alkermes plc (ALKS) Phase 1 Study of ALKS 7106 Fails, Further Development Halted
February 24, 2015 7:05 AM ESTAlkermes plc (NASDAQ: ALKS) today announced topline results from a phase 1 clinical study of ALKS 7106, a new molecule intended for the treatment of pain. The randomized, double-blind, placebo-controlled study was designed to evaluate the safety, tolerability and pharmacokinetics of single escalating doses of ALKS 7106 in 64 healthy adults. Data from the study showed that ALKS 7106 did not meet... More
Alkermes plc (ALKS) Tops Q4 EPS by 7c; Guides FY15
February 24, 2015 7:03 AM ESTAlkermes plc (NASDAQ: ALKS) reported Q4 EPS of $0.11, $0.07 better than the analyst estimate of $0.04. Revenue for the quarter came in at $175.2 million versus the consensus estimate of $161.7 million.
Alkermes plc sees FY2015 EPS of $0.27-$0.40, versus the consensus of $0.20. Alkermes plc sees FY2015... More
